ArticleClinical ophthalmology (Auckland, N.Z.)2025
Reduced Ocular Surface Inflammation in SMILE Patients: The Beneficial Outcome of 0.1% Ciclosporin Cationic Emulsion Treatment.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: After laser refractive surgery, dry eye disease is a common issue, primarily caused by inflammation. In a cohort of patients undergoing small incision lenticule extraction (SMILE), we examined the impact of anti-inflammatory drug ciclosporin (0.1% in cationic emulsion; CsA-CE) on the corneal fluorescein staining (CFS) score and other indicators of dry eye disease. Methods: This non-randomized, interventional, comparative study enrolled 30 patients undergoing SMILE, who received a once-daily, preservative-free, single-dose formulation of CsA-CE for one month following surgery. Tear osmolarity, ocular surface disease index (OSDI) scores, and CFS scores were measured after one- and three-months following surgery and compared to a control group (n=30). In the CsA-CE group, 26 patients completed the follow-up at Month 1, compared to 28 patients in the control group. At three-months follow-up, 22 patients in the CsA-CE group and 23 in the control group remained. Results: At Month 1 and Month 3 postoperative follow-up, the CsA CE group's CFS scores were significantly lower compared to controls: 0.31 ± 0.74 vs 0.75 ± 0.89 (P = 0.02) and 0.05 ± 0.21 vs 0.43 ± 0.84 (P = 0.04), respectively. Mean CFS scores of CsA-CE group were 0.44 (Month 1) and 0.38 (Month 3) lower postoperatively, compared to the control group. Tear osmolarity and OSDI scores, however, did not significantly differ between the two groups and stayed within normal bounds. With 57.7% of patients reporting no instillation site pain and no other side effects, the treatment was well-tolerated. Conclusion: The anti-inflammatory effect of CsA-CE application in the early postoperative period after SMILE resulted in significantly lower CFS scores at Months 1 and 3 in comparison to the control group. These results suggest that 0.1% CsA-CE treatment lowers ocular surface damage and might thus benefit the recovery process of patients treated with this form of laser refractive surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.